Revance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Jessica Serra – Head-Investor Relations and ESG Mark Foley – Chief Executive Officer Dustin Sjuts – President Toby Schilke – Chief Financial Officer Conference Call Participants Ken Cacciatore – Cowen and Co Seamus Fernandez – Guggenheim David Amsellem – Piper Sander Annabel Samimy – Stifel Balaji Prasad – Barclays Vamil Divan – Mizuho Securities Douglas Tsao – H.C. Wainwright Rohit Bhasin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) Delaware 77-0551645 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition perio ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2021 Earnings Conference Call February 28, 2022 4:30 PM ET Company Participants Jessica Serra - Head, IR & and ESG Mark Foley - CEO Dustin Sjuts - President Toby Schilke - CFO Conference Call Participants Ken Cacciatore - Cowen and Company Alena Seamus Fernandez - Guggenheim David Amsellem - Piper Sandler Annabel Samimy - Stifel Balaji Prasad - Barclays Tim Lugo - William Blair Douglas Tsao - H.C. Wainwright Serge Belanger - Needham & Company Disclaimer*: This tra ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0551645 State or other juris ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2021 Earnings Conference Call November 9, 2021 4:30 PM ET Company Participants Jessica Serra - IR Mark Foley - CEO Dustin Sjuts - President Toby Schilke - CFO Roman Rubio - SVP, Clinical Development Conference Call Participants Ken Cacciatore - Cowen and Company David Amsellem - Piper Sandler Seamus Fernandez - Guggenheim Nick Rubino - Stifel Vamil Divan - Mizuho Tim Lugo - William Blair Operator Welcome to Revance Therapeutics Third Quarter 2021 Financial Results ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0551645 (State or o ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Jessica Serra - Head, IR and ESG Mark Foley - President and CEO Toby Schilke - CFO Dr. Abhay Joshi - COO and President, R&D and Product Operations Dustin Sjuts - Chief Commercial Officer, Aesthetics and Therapeutics Aubrey Rankin - President, Innovation and Technology Conference Call Participants Seamus Fernandez - Guggenheim Terence Flynn - Goldman Sachs Annabel Samimy - Stifel David Ams ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0551645 (State or other ...

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2021 Results Conference Call May 10, 2021 4:30 PM ET Company Participants Jessica Serra - Head, IR and ESG Mark Foley - President and CEO Toby Schilke - CFO Dr. Abhay Joshi - COO and President, R&D and Product Operations Dustin Sjuts - Chief Commercial Officer, Aesthetics and Therapeutics Aubrey Rankin - President, Innovation and Technology Conference Call Participants Ken Cacciatore - Cowen & Company Seamus Fernandez - Guggenheim Terence Flynn - Goldman Sachs Ann ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File No. 001-36297 Revance Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 77-0551645 (State or other ...